203 related articles for article (PubMed ID: 35902282)
21. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
22. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
23. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.
Liu Y; Hu G; Wang Y; Ren W; Zhao X; Ji F; Zhu Y; Feng F; Gong M; Ju X; Zhu Y; Cai X; Lan J; Guo J; Xie M; Dong L; Zhu Z; Na J; Wu J; Lan X; Xie Y; Wang X; Yuan Z; Zhang R; Ding Q
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33658332
[TBL] [Abstract][Full Text] [Related]
24. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
[TBL] [Abstract][Full Text] [Related]
25. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages.
Satta S; Meng Z; Hernandez R; Cavallero S; Zhou T; Hsiai TK; Zhou C
Theranostics; 2022; 12(6):2639-2657. PubMed ID: 35401811
[No Abstract] [Full Text] [Related]
26. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes.
Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL
J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
[TBL] [Abstract][Full Text] [Related]
28. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
Mou H; Quinlan BD; Peng H; Liu G; Guo Y; Peng S; Zhang L; Davis-Gardner ME; Gardner MR; Crynen G; DeVaux LB; Voo ZX; Bailey CC; Alpert MD; Rader C; Gack MU; Choe H; Farzan M
PLoS Pathog; 2021 Apr; 17(4):e1009501. PubMed ID: 33836016
[TBL] [Abstract][Full Text] [Related]
29. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
Heurich A; Hofmann-Winkler H; Gierer S; Liepold T; Jahn O; Pöhlmann S
J Virol; 2014 Jan; 88(2):1293-307. PubMed ID: 24227843
[TBL] [Abstract][Full Text] [Related]
30. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.
Chan KK; Tan TJC; Narayanan KK; Procko E
Sci Adv; 2021 Feb; 7(8):. PubMed ID: 33597251
[TBL] [Abstract][Full Text] [Related]
31. Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants.
Dehghani J; Movafeghi A; Mathieu-Rivet E; Mati-Baouche N; Calbo S; Lerouge P; Bardor M
Mar Drugs; 2022 Oct; 20(11):. PubMed ID: 36354980
[TBL] [Abstract][Full Text] [Related]
32. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.
Lei C; Qian K; Li T; Zhang S; Fu W; Ding M; Hu S
Nat Commun; 2020 Apr; 11(1):2070. PubMed ID: 32332765
[TBL] [Abstract][Full Text] [Related]
33. A decoy mutant ACE2 designed to reduce COVID-19.
Maishan M; Lim DL; Zimmerman GA; Matthay MA
Trends Pharmacol Sci; 2022 Sep; 43(9):703-705. PubMed ID: 35282893
[TBL] [Abstract][Full Text] [Related]
34. ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.
Alfaleh MA; Alsulaiman RM; Almahboub SA; Nezamuldeen L; Zawawi A; Aljehani ND; Yasir M; Abdulal RH; Alkhaldi R; Helal A; Alamri SS; Malki J; Alhabbab RY; Abujamel TS; Alhakamy NA; Alnami A; Algaissi A; Hassanain M; Hashem AM
Antib Ther; 2024 Jan; 7(1):53-66. PubMed ID: 38371953
[TBL] [Abstract][Full Text] [Related]
35. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
36. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
37. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
Ameratunga R; Lehnert K; Leung E; Comoletti D; Snell R; Woon ST; Abbott W; Mears E; Steele R; McKee J; Muscroft-Taylor A; Ameratunga S; Medlicott N; Das S; Rolleston W; Quiñones-Mateu M; Petousis-Harris H; Jordan A
N Z Med J; 2020 May; 133(1515):112-118. PubMed ID: 32438383
[TBL] [Abstract][Full Text] [Related]
38. Drug screening and development from the affinity of S protein of new coronavirus with ACE2.
Jiang YP; Zhao XX; Lv HQ; Wen CP
Eur J Clin Microbiol Infect Dis; 2021 Apr; 40(4):715-723. PubMed ID: 33034780
[TBL] [Abstract][Full Text] [Related]
39. A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells.
Kegler A; Drewitz L; Arndt C; Daglar C; Rodrigues Loureiro L; Mitwasi N; Neuber C; González Soto KE; Bartsch T; Baraban L; Ziehr H; Heine M; Nieter A; Moreira-Soto A; Kühne A; Drexler JF; Seliger B; Laube M; Máthé D; Pályi B; Hajdrik P; Forgách L; Kis Z; Szigeti K; Bergmann R; Feldmann A; Bachmann M
Front Immunol; 2023; 14():1204543. PubMed ID: 37383226
[TBL] [Abstract][Full Text] [Related]
40. Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection.
Ren W; Zhu Y; Lan J; Chen H; Wang Y; Shi H; Feng F; Chen DY; Close B; Zhao X; Wu J; Tian B; Yuan Z; Zhou D; Saeed M; Wang X; Zhang R; Ding Q
J Virol; 2022 Jan; 96(1):e0149221. PubMed ID: 34668773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
